This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Francine M. Benes, MD, PhD
Laboratory for Structural Neuroscience McLean Hospital 115 Mill St Belmont, MA 02178 Dr Benes is supported by grants MH00423, MH42261, and MH31154 from the National Institute of Mental Health, Rockville, Md, and by an award from the Stanley Foundation, Arlington, Va.

Arch Gen Psychiatry. 1995;52(12):1015-1018.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The arthcle in this issue of the ARCHIVES entitled "Glutamate Receptor Dysfunction and Schizophrenia" by Olney and Farber¹ presents a provocative hypothesis concerning the role of N-methyl-Daspartate (NMDA)—mediated glutamatergic dysfunction in the pathophysiology of schizophrenia. The ideas have evolved out of Dr Olney's studies of phencyclidine (PCP)-induced neurotoxicity in the cingulate and retrosplenial cortices of the rat brain and his subsequent efforts to elucidate the neuropharmacological characteristics of this effect. It is timely that the authors have brought together this body of work and that they have used it to model several key questions concerning schizophrenia. Toward this end, the article focused primarily on animal investigations to support the details of the model circuit they presented in Figure 4. It is noteworthy that other data from postmortem studies can corroborate several aspects of the Olney and Farber model, particularly the central idea that there may be . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?